Orchid Pharma share news, announcements and annual reports
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Orchid Pharma Limited · Formerly Orchid Chemicals & Pharmaceuticals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993 on BSE, Jul 2010 on NSE
Last close ₹836.45down ₹56.95 (6.37%)BSE ₹833.05
Share price at the NSE close on 30 Oct 2026. Previous close ₹893.40.
30 Oct: open ₹893.45, high ₹893.45, low ₹830.00
52-week range of traded prices to 30 Oct 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,009 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 88,12456.8% delivered
Orchid Pharma orders, deals and press releases
141 filed, newest first. Page 2 of 3.
Oct 2015
Aug 2015
May 2015
Dec 2014
Nov 2014
Jul 2014
Jun 2014
Feb 2014
May 2013
Apr 2013
Feb 2013
Nov 2012
Aug 2012
May 2012
18 May · Business
Allotment Committee of the Board of Directors has allotted 10,000 equity shares of Rs.10 each upon exercise of vested options by one of the employees under ESOP-2010 scheme on May 17, 2012.
Apr 2012
Feb 2012
Jan 2012
Dec 2011
Nov 2011
Aug 2011
Jul 2011
Jun 2011
May 2011
Jan 2011
Nov 2010
Oct 2010
Jul 2010
Jun 2010
May 2010
Apr 2010
29 Apr · Business
Press release dated April 29, 2010, titled "Orchid settles Litigation with Forest Laboratories for Memantine Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
31 Mar · Business
Press release dated March 30, 2010 titled "Orchid completes Business Transfer transaction with Hospira, Inc". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
29 Jan · Business
Media release dated January 29, 2010, titled "Orchid registers turnover of Rs 332 crore during Q3 FY10". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Jan · Business
Media release dated January 08, 2010, titled "Orchid receives Tentative US FDA nod for Memantine Tablets". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
16 Dec · Business
Board at its meeting held on December 15, 2009, has approved the sale and transfer of its generic injectables pharmaceuticals business to Hospira, Inc., USA. The acquisition by Hospira includes Orchid's beta-lactam antibiotics manufacturing complex (comprising cephalosporin, penicillin and carbapenem facilities) and pharmaceutical research and development (R&D) facility at Irungattukottai (Chennai), India as well as its generic injectable product portfolio and pipeline. Hospira would have access to the talented bases of employees dedicated to this business as part of this transaction. This transaction is subject to Orchid's shareholders', regulatory and legal approvals, as well as customary closing conditions. A copy of the press release issued by the company dated December 15, 2009 titled "Hospira To Acquire Orchid's Generic Injectable Pharmaceuticals Business" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
30 Oct · Business
Press release dated October 30, 2009 titled "Orchid registers revenue of Rs 314 crore during Q2 FY10". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Oct · Business
Press release dated October 19, 2009, titled "Orchid awarded the Corporate Social Responsibility Award 2008-09 by Government of Tamilnadu". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2009
25 Sep · Business
Press release issued by the company, regarding an updated note on Piperacillin Tazobactam product in the US. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Sep · Business
Press release regarding an Information note on Piperacillin Tazobactam. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Sep · Business
Media release dated September 18, 2009, titled "Orchid receives final US FDA nod for Zaleplon Capsules". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.